增效达芦那韦联合利匹韦林在长期HIV-1感染患者中的有效性:DARIL研究
48周时87.7%的患者VL<50 copies/mL,基线VL检测不到者有效性为91.1%,可检测者为80%,无新发耐药突变。
要点
- 经治长期HIV感染患者中,48周病毒学抑制率达87.7%
- 基线VL检测不到者有效性91.1%,可检测者为80%
- 4例病毒学失败均未出现新发耐药突变,其中3例维持原方案再抑制
核心结论
- 增效达芦那韦联合利匹韦林在经治、长期HIV感染且存在既往耐药的患者中显示出良好有效性和耐受性。
主要发现
- 48周时71例(87.7%)患者VL<50 copies/mL。
- 基线VL检测不到者有效性91.1%,基线VL可检测者有效性80%。
- 4例病毒学失败,无新发耐药突变,其中3例维持原方案后病毒血症再抑制。
- 47例有历史基因型:41例(87.2%)存在NRTI耐药突变,21例(44.7%)存在NNRTI耐药突变,12例(25.5%)存在原发性PI耐药突变,7例(14.9%)存在INSTI耐药突变。
- 1例对增效达芦那韦低水平耐药,5例对利匹韦林存在一定耐药。
关键数值与推荐
- 主要终点为48周时VL<50 copies/mL的患者百分比。
- 启动治疗的主要原因:简化治疗44%、肾或骨毒性28.6%、病毒学失败17.9%。
- 基线VL可检测者中位VL为202(IQR 98-340)copies/mL。
临床怎么用
- 对于经治、存在既往耐药且需简化治疗或存在肾骨毒性的长期HIV感染者,可考虑增效达芦那韦联合利匹韦林两药方案。
局限性
- 回顾性队列研究,样本量较小(84例),仅来自西班牙9家医院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of boosted darunavir plus rilpivirine, once daily, could be a convenient, effective and well-tolerated two-drug regimen to achieve HIV suppression in HIV-infected patients. METHODS: Multicentre, retrospective cohort study in nine hospitals in Spain. All HIV-infected subjects starting boosted darunavir plus rilpivirine were included, irrespective of their viral load (VL). The primary objective was the percentage of patients with VL <50 copies/mL at 48 weeks. Secondary objectives included changes in CD4+ cell count, lipid profile and renal function. RESULTS: Eighty-one of 84 patients reached Week 48. Fifty-nine (70.2%) patients had VL <50 copies/mL at baseline and the rest had a median VL of 202 (IQR 98-340) copies/mL. Subjects had a median of 21 years of infection with six prior regimens. The main reasons for starting boosted darunavir plus rilpivirine were simplification (44%), kidney or bone toxicity (28.6%) and virological failure (17.9%). Historical genotypes from 47 patients showed 41 (87.2%) patients with NRTI RAMs, 21 (44.7%) with NNRTI RAMs, 12 (25.5%) with primary PI RAMs and 7 (14.9%) with integrase strand transfer inhibitor (INSTI) RAMs. One patient had low-level resistance to boosted darunavir and five patients had some resistance to rilpivirine. At 48 weeks, 71 (87.7%) patients had VL <50 copies/mL. According to undetectable or detectable baseline VL, effectiveness was 91.1% or 80%, respectively. There were four virological failures with no emergence of new RAMs. Three of these patients resuppressed viraemia while maintaining the same regimen. CONCLUSIONS: The combination of boosted darunavir plus rilpivirine has shown good effectiveness and tolerability in this cohort of pretreated patients with a long-lasting HIV infection, exposure to multiple antiretroviral regimens and prior HIV resistance.
引用
- Navarro J, González-Cordón A, Casado JL, et al. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. J Antimicrob Chemother. 2020. PMID: 32134108. doi:10.1093/jac/dkaa072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。